A Panel of Biomarkers in Diagnosing Late-onset Neonatal Sepsis and Necrotizing Enterocolitis in Sibu Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-01

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a cross-sectional study to evaluate the utilities of a panel of biomarkers (Procalcitonin, Interleukin-6, Serum Amyloid A and Apolipoprotein C2) versus the gold standard blood culture result diagnosing late-onset neonatal sepsis (LONS) and/or necrotizing enterocolitis (NEC). Neonates who meet the initial screening criteria for suspected LONS or NEC will be recruited into the study. A group of 50 neonates who are clinically well, admitted to the nursery or general ward for reasons other than neonatal sepsis or NEC will also be recruited into the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Performance of Interleukin-27 Cord Blood Level as A Biomarker Predicating Early Onset Neonatal Sepsis

NCT05589909

Neonatal Sepsis, Early-Onset

UNKNOWN

Evaluation of bioMarkErs to Reduce Antibiotics Use in hospitalizeD nEonates

NCT03299751

Late-Onset Neonatal Sepsis

COMPLETED NA

NeoAMR Observational Study in Neonatal Sepsis

NCT03721302

Neonatal SEPSIS

COMPLETED

Analysis of Differential Proteins and Maternal Influencing Factors of Septic Shock in Neonates

NCT06206590

Neonatal Disease

RECRUITING

Procalcitonin in Diagnosis of Bacterial Infections in Young Infants

NCT03509727

Sepsis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The diagnosis of neonatal sepsis is challenging especially the very low birth weight infants as the signs and symptoms of sepsis are nonspecific and can be attributed to non-infected aetiologies including exacerbation of bronchopulmonary dysplasia, apnoea of prematurity and gastroesophageal reflux. Blood culture remains the gold standard for diagnosing septicaemia (either bacteremia or fungemia). However, its effectiveness in the population of preterm infants is compromised.Given the dire consequences of not treating the sepsis early, clinicians tend to have a low threshold for treatment. This leads to overuse of antimicrobials, promotion of antimicrobial resistance, exposure of infants to avoidable side effects from the antimicrobial treatment, prolonged hospitalisation and increased healthcare costs. Hence, there is a need for a clearly defined algorithm for diagnosing LONS and NEC. This study aims to examine the diagnostic utilities of a panel of sepsis biomarkers and explore if they can be incorporated into a diagnostic algorithm which hopefully, can be translated into clinical practice in the future.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neonatal SEPSIS Necrotizing Enterocolitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neonates with suspected LONS and/or NEC

A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.

No intervention

Intervention Type OTHER

No intervention will be given to study subjects. Only blood will be obtained from study subjects.

Healthy neonates

A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.

No intervention

Intervention Type OTHER

No intervention will be given to study subjects. Only blood will be obtained from study subjects.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention will be given to study subjects. Only blood will be obtained from study subjects.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants with signs and symptoms suggestive of sepsis and/or NEC and requiring full sepsis screening and start of intravenous antibiotic(s), or a change of antibiotics (if already on)
* Infants with postnatal age greater than 72 hours and less than 28 days of life, of all gestation
* Parents of potential neonates who are willing to give written informed consent

Healthy subjects

* Clinically well infants admitted to Sibu Hospital for reasons other than neonatal sepsis or NEC
* Infants with postnatal age greater than 72 hours and less than 28 days of life, of all gestation

Exclusion Criteria

* Infants who have lethal or life-threatening congenital abnormalities
* Infants who have chromosomal abnormalities
* Infants who have hypoxic ischemic encephalopathy
* Infants who are on steroid treatment
* Infants who received blood transfusions
* Post-operative infants

Minimum Eligible Age

72 Hours

Maximum Eligible Age

30 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No